• Something wrong with this record ?

Frequent intravenous pulses of growth hormone together with alanylglutamine supplementation in prolonged critical illness after multiple trauma: effects on glucose control, plasma IGF-I and glutamine

F Duska, M Fric, J Pazout, P Waldauf, P Tuma, J Pachl

. 2008 ; 18 (1) : 82-87.

Language English Country Great Britain

Document type Randomized Controlled Trial

Grant support
NR8230 MZ0 CEP Register

OBJECTIVE: We aim to demonstrate that low dose growth hormone (GH) administered in i.v. pulses every 3h is able to normalize IGF-I levels in subjects with prolonged critical illness, after multiple trauma. We also ask whether it is possible to control glycaemia during such a treatment and how alanylglutamine (AG) supplementation influences plasma glutamine concentration. METHODS: We used a prospective double-blind (group 1 vs. 2), randomized trial with an open-label control arm (group 3). Thirty multiple trauma patients (median age: 36, 42, 46 years) were randomized on day 4 after trauma to receive (group 1, n=10) i.v. AG supplementation (0.3 g/kg day from day 4 till 17) and i.v. GH (0.05 mg/kg day divided into 8 boluses, maximum dose at 3 AM, administered on days 7-17) or AG and placebo (group 2, n=10). Group 3 (n=10) received isocaloric isonitrogenous (proteins 1.5 g/kg day) nutrition without AG. Glycaemia was controlled by i.v. insulin infusion according to a routine protocol. RESULTS: GH treatment caused an increase of IGF-I (from median 169 on day 4 to 493 ng/ml on day 17), IGFBP-3 (from 2.4 to 3.2 microg/ml) and a fall in IGFBP-1 (from 11.5 to 3.1 microg/ml), whilst in both groups 2 and 3 these indices remained unchanged. At the end of the study (day 17) IGF-I and IGFBP-1 differed significantly among groups (p=0.008 resp. p=0.010, Kruskal-Wallis). Plasma glutamine remained below the normal range through the study in all groups (median: 0.18-0.30 mM), but had a tendency to rise in group 2 in contrast with a fall in groups 1 and 3 (NS). Group 1 required more insulin (p<0.01) than did the control group but median glycaemia was only 0.4-0.5 mM higher in group 1 (6.5 mM) than in groups 2 and 3 (6.1 resp. 6.0 mM). CONCLUSIONS: GH (0.05 g/kg day) administered in i.v. pulses is able to normalize IGF-I levels in subjects with prolonged critical illness after trauma. During this treatment, the standard dose of AG prevents worsening of plasma glutamine deficiency and glucose control is possible using routine algorithms, but it requires higher insulin doses.

000      
02103naa 2200433 a 4500
001      
bmc11003022
003      
CZ-PrNML
005      
20131002105020.0
008      
110225s2008 xxk e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Duška, František, $d 1976- $7 mzk2007386027
245    10
$a Frequent intravenous pulses of growth hormone together with alanylglutamine supplementation in prolonged critical illness after multiple trauma: effects on glucose control, plasma IGF-I and glutamine / $c F Duska, M Fric, J Pazout, P Waldauf, P Tuma, J Pachl
314    __
$a Department of Anaesthesia and Critical Care Medicine, Charles University, 3rd Faculty of Medicine, Srobarova 50, Prague, Czech Republic. fduska@yahoo.com
520    9_
$a OBJECTIVE: We aim to demonstrate that low dose growth hormone (GH) administered in i.v. pulses every 3h is able to normalize IGF-I levels in subjects with prolonged critical illness, after multiple trauma. We also ask whether it is possible to control glycaemia during such a treatment and how alanylglutamine (AG) supplementation influences plasma glutamine concentration. METHODS: We used a prospective double-blind (group 1 vs. 2), randomized trial with an open-label control arm (group 3). Thirty multiple trauma patients (median age: 36, 42, 46 years) were randomized on day 4 after trauma to receive (group 1, n=10) i.v. AG supplementation (0.3 g/kg day from day 4 till 17) and i.v. GH (0.05 mg/kg day divided into 8 boluses, maximum dose at 3 AM, administered on days 7-17) or AG and placebo (group 2, n=10). Group 3 (n=10) received isocaloric isonitrogenous (proteins 1.5 g/kg day) nutrition without AG. Glycaemia was controlled by i.v. insulin infusion according to a routine protocol. RESULTS: GH treatment caused an increase of IGF-I (from median 169 on day 4 to 493 ng/ml on day 17), IGFBP-3 (from 2.4 to 3.2 microg/ml) and a fall in IGFBP-1 (from 11.5 to 3.1 microg/ml), whilst in both groups 2 and 3 these indices remained unchanged. At the end of the study (day 17) IGF-I and IGFBP-1 differed significantly among groups (p=0.008 resp. p=0.010, Kruskal-Wallis). Plasma glutamine remained below the normal range through the study in all groups (median: 0.18-0.30 mM), but had a tendency to rise in group 2 in contrast with a fall in groups 1 and 3 (NS). Group 1 required more insulin (p<0.01) than did the control group but median glycaemia was only 0.4-0.5 mM higher in group 1 (6.5 mM) than in groups 2 and 3 (6.1 resp. 6.0 mM). CONCLUSIONS: GH (0.05 g/kg day) administered in i.v. pulses is able to normalize IGF-I levels in subjects with prolonged critical illness after trauma. During this treatment, the standard dose of AG prevents worsening of plasma glutamine deficiency and glucose control is possible using routine algorithms, but it requires higher insulin doses.
650    _2
$a dospělí $7 D000328
650    _2
$a krevní glukóza $x metabolismus $7 D001786
650    _2
$a kritický stav $7 D016638
650    _2
$a dipeptidy $x aplikace a dávkování $7 D004151
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a způsoby aplikace léků $7 D004333
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glutamin $x krev $7 D005973
650    _2
$a růstový hormon $x aplikace a dávkování $7 D013006
650    _2
$a lidé $7 D006801
650    _2
$a insulinu podobný růstový faktor I $x analýza $7 D007334
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a polytrauma $x farmakoterapie $7 D009104
650    _2
$a financování organizované $7 D005381
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Fric, Michal. $7 xx0241106
700    1_
$a Pažout, Jaroslav $7 xx0137181
700    1_
$a Waldauf, Petr $7 xx0085547
700    1_
$a Tůma, Petr $7 xx0105786
700    1_
$a Pachl, Jan, $d 1949- $7 nlk19990073644
773    0_
$t Growth Hormone & Igf Research $w MED00005163 $g Roč. 18, č. 1 (2008), s. 82-87 $x 1096-6374
910    __
$a ABA008 $b x $y 1
990    __
$a 20110413114001 $b ABA008
991    __
$a 20131002105537 $b ABA008
999    __
$a ok $b bmc $g 830425 $s 695014
BAS    __
$a 3
BMC    __
$a 2008 $b 18 $c 1 $d 82-87 $i 1096-6374 $m Growth hormone & IGF research $n Growth Horm IGF Res $x MED00005163
GRA    __
$a NR8230 $p MZ0
LZP    __
$a 2011-2B/dkme

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...